Sign in

ZVSA on OTC

ZyVersa Therapeutics, Inc.

ZyVersa Therapeutics, Inc. is an American pharmaceutical preparations company, incorporated in Delaware.1 It is headquartered in Lighthouse Point, Florida.1 Its shares trade on OTC under the symbol ZVSA.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerZVSA on OTC1
  • IndustryPharmaceutical Preparations1
  • HeadquartersLighthouse Point, Florida1
  • Incorporated inDE2
  • Business address2436 North Federal Highway, Suite 466, Lighthouse Point, Fl 330642
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2

See how the biggest companies compare on our leaderboards

100’s preclinical data, refer to the IC 100 White Paper at https://investors.zyversa.com/static-files/64964310-ab95-4a06-bc47-dd44c63dc5c7.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income456-$25.5M in 2025+96% since 2022
-$150.0M-$100.0M-$50.0M02022: -$13.0M-$13.0M20222023: -$107.8M-$107.8M2023+728%2024: -$9.1M-$9.1M2024−92%2025: -$25.5M-$25.5M2025+179%
Net income456-$25.0M in 2025+78% since 2022
-$100.0M-$75.0M-$50.0M-$25.0M02022: -$14.0M-$14.0M20222023: -$98.3M-$98.3M2023+600%2024: -$9.4M-$9.4M2024−90%2025: -$25.0M-$25.0M2025+165%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Research and development$1.1M$1.8M
General and administrative$5.7M$7.4M
Impairment of in-process research and development$18.6M
Total Operating Expenses$25.5M$9.1M
Loss From Operations-$25.5M-$9.1M
Interest expense$513.2K$269.9K
Change in fair value of equity payable-$201.9K
Pre-Tax Net Loss-$25.8M-$9.4M
Income tax benefit (provision)$851.7K-$6.7K
Net Loss-$25.0M-$9.4M
Basic-$4.18-$8.48
Diluted-$4.18-$8.48
Basic6.0M shares1.1M shares
Diluted6.0M shares1.1M shares

Compare ZyVersa Therapeutics, Inc. with another company

Corporate structure

ZyVersa Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of ZyVersa Therapeutics, Inc.

  • ZyVersa Therapeutics, Inc. Lighthouse Point, Florida

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What ZyVersa Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$52.0K6 Dec 31, 2025$52.0K6 Dec 31, 20240%
Accumulated depreciation$52.0K6 Dec 31, 2025$52.0K6 Dec 31, 20240%

Properties, in its own words

Our principal executive offices are located at 2200 North Commerce Parkway, Suite 208, Weston, Florida 33326. On January 18, 2019, we entered into a lease agreement (the “Lease”) for 3,502 square feet of office space located at this facility, with a lease term of 60 months beginning in January 2019 and ending in January 2024. On January 15, 2024, the Company extended the lease for an additional year and on January 9, 2025, the Company extended the lease for an additional year. The lease agreement ended on January 31, 2026 and it was not extended.

Item 2 of the 10-K filed Mar 31, 2026.3

Leadership

Who has led ZyVersa Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Steve C. Glover2022–now

Chief financial officer

  1. David S. Briones2021–2022
  2. Peter Wolfe2022–now
2025
Board members and other officers (13)

Former names

  • Larkspur Health Acquisition Corp.May 13, 2021 to Dec 9, 20222

Timeline

  1. Jul 16, 20268-K Other events25
  2. Jul 10, 20268-K Executive or director change; Other events26
  3. Mar 5, 20268-K Entered a material agreement27
  4. Dec 3, 20258-K Executive or director change28
  5. Nov 19, 20258-K Results of operations29
  6. Oct 15, 20258-K Executive or director change30
  7. Sep 18, 20258-K Listing notice or transfer31
  8. Jul 28, 20258-K Other events32
  9. Jul 16, 20258-K Listing notice or transfer33
  10. Jul 9, 20258-K Entered a material agreement; Unregistered sale of shares34
  11. Jun 25, 20258-K Entered a material agreement; Unregistered sale of shares; Other events35
  12. Jun 12, 20258-K Executive or director change; Shareholder vote36
  13. Dec 13, 2022New chief executive Steve C. Glover becomes CEO11

Calendar

When it reported results

  1. Nov 19, 2025Reported quarterly or annual results29
  2. Nov 14, 2024Reported quarterly or annual results37
  3. May 15, 2023Reported quarterly or annual results38
  4. Apr 3, 2023Reported quarterly or annual results39

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

307 filings to the SEC since October 2021: 6 annual reports, 13 quarterly reports, 52 major events, 51 insider forms, 25 large holders, 160 other. The latest 20:

  1. Jul 16, 20268-K EDGAR
  2. Jul 10, 20268-K EDGAR
  3. May 13, 202610-Q EDGAR
  4. Mar 31, 202610-K EDGAR
  5. Mar 5, 20268-K EDGAR
  6. Dec 3, 20258-K EDGAR
  7. Nov 19, 20258-K EDGAR
  8. Nov 19, 202510-Q EDGAR
  9. Nov 14, 2025NT 10-Q EDGAR
  10. Oct 15, 20258-K EDGAR
  11. Oct 6, 202525-NSE EDGAR
  12. Sep 18, 20258-K EDGAR
  13. Aug 14, 2025SCHEDULE 13G/A EDGAR
  14. Aug 13, 202510-Q EDGAR
  15. Aug 6, 2025EFFECT EDGAR
  16. Aug 5, 2025CORRESP EDGAR
  17. Aug 1, 2025CORRESP EDGAR
  18. Aug 1, 2025S-1/A EDGAR
  19. Jul 30, 2025UPLOAD EDGAR
  20. Jul 28, 20258-K EDGAR

The 307 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024Stephen C. Glover65$550.0K54
2024Peter Wolfe57$395.0K54
2024Pablo A. GuzmanM.D.75$350.0K54
2023Co-FounderChief Executive Officer, President and Chairman$550.0K$993.2K54
2023Chief Financial Officer and Secretary$395.0K$573.4K54
2023Chief Medical Officer and Senior Vice President of Medical Affairs$320.8K$506.2K54

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$213.5K 2020–2020
Money received by yearMoney received by year, 2020–2020: $213.5K in all. PPP loans $213.5K.$0$100K$200K$300K2020 · PPP loans: $213.5K2020
Figures by year
YearPPP loansTotal
2020$213.5K$213.5K

PPP loans

Paycheck Protection Program loans of $150,000 and up, approved April 2020 to July 2021, from the SBA55. Matched to this company by name and state.

  1. May 1, 2020$213.5K PPP loan (first draw) from Wells Fargo Bank, National Association55To ZYVERSA THERAPEUTICS INC, Weston FL; $216.2K forgiven Aug 13, 2021

SEC filer profile

How ZyVersa Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARZyVersa Therapeutics, Inc.1
  • CIK0001859007
  • Employer ID (EIN)86-26857443
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address2436 North Federal Highway, Suite 466, Lighthouse Point, FL 330641
  • Phone908-370-51021
  • Shares outstanding8,095,921 as of May 11, 20269
  • Public float$3.3M as of Jun 30, 20253
  • AuditorCBIZ CPAs P.C., New York, NY PCAOB ID 1993
  • On EDGAR sinceMay 13, 20211
  • Filings318 in all: 8-K (49), CORRESP (48), 4 (34), S-1/A (21), UPLOAD (20), 3 (17), 10-Q (13), EFFECT (12)1
    All 39 form types

    SC 13G (11), 424B3 (10), SC 13G/A (8), S-1 (6), 10-K (5), 424B4 (5), 425 (5), DEF 14A (5), PRE 14A (5), DEFA14A (4), S-3 (4), 25-NSE (3), 8-K/A (3), ARS (3), S-4/A (3), S-8 (3), CERT (2), NT 10-Q (2), POS EX (2), SC 13D (2), SC 13D/A (2), SEC STAFF LETTER (2), 10-K/A (1), 424B5 (1), 8-A12B (1), 8-A12B/A (1), NT 10-K (1), POS AM (1), S-4 (1), SCHEDULE 13G (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) May 13, 2026
    Proxy statement (DEF 14A) Apr 17, 2025
    Latest 8-K (8-K) Jul 16, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.0001 par value per shareZVSA

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks ZyVersa Therapeutics, Inc. names in Item 1A of its 10-K filed Mar 31, 2026: 2 risks under these headings, as written.3

  • We have never been profitable.
  • Our common stock has been delisted from The Nasdaq Capital Market.

Legal proceedings

We are not currently subject to any material legal proceedings; however, we may from time to time become a party to various legal proceedings arising in the ordinary course of our business. Although the results of litigation and claims cannot be predicted with certainty, as of the date of this report, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
    SEC EDGAROther events
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55